Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $195.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price objective raised by HC Wainwright from $140.00 to $195.00 in a research note issued to investors on Monday morning, MarketBeat reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q3 2026 earnings at $0.07 EPS, Q4 2026 earnings at ($0.11) EPS, Q1 2027 earnings at $0.09 EPS, Q2 2027 earnings at $0.18 EPS, Q3 2027 earnings at $0.35 EPS, Q4 2027 earnings at $0.80 EPS, FY2027 earnings at $1.42 EPS, FY2028 earnings at $5.38 EPS, FY2029 earnings at $7.21 EPS and FY2030 earnings at $10.03 EPS.

Several other research analysts also recently commented on MIRM. Weiss Ratings upgraded Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday, August 6th. Morgan Stanley set a $137.00 price target on Mirum Pharmaceuticals in a research report on Thursday, August 6th. Citigroup reissued a “market outperform” rating on shares of Mirum Pharmaceuticals in a report on Thursday, August 27th. Citizens Jmp restated a “market outperform” rating and issued a $137.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, August 27th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $142.56.

Mirum Pharmaceuticals Trading Down 2.4%

NASDAQ:MIRM opened at $85.48 on Monday. Mirum Pharmaceuticals has a 1 year low of $63.23 and a 1 year high of $130.00. The stock’s fifty day moving average price is $99.16 and its two-hundred day moving average price is $101.42. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. The company has a market cap of $5.55 billion, a P/E ratio of -5.87 and a beta of 0.49.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The company had revenue of $176.24 million during the quarter, compared to analysts’ expectations of $166.33 million. During the same quarter last year, the firm posted ($0.12) earnings per share. Mirum Pharmaceuticals’s revenue for the quarter was up 37.9% compared to the same quarter last year. As a group, analysts expect that Mirum Pharmaceuticals will post -1.31 EPS for the current year.

Insider Activity at Mirum Pharmaceuticals

In related news, SVP Jolanda Howe sold 658 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $100.00, for a total transaction of $65,800.00. Following the completion of the transaction, the senior vice president directly owned 616 shares in the company, valued at $61,600. The trade was a 51.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 6,001 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total value of $599,499.90. Following the completion of the transaction, the chief financial officer owned 36,355 shares in the company, valued at $3,631,864.50. This represents a 14.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 123,499 shares of company stock valued at $12,854,484. Company insiders own 8.32% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MIRM. Engineers Gate Manager LP raised its stake in Mirum Pharmaceuticals by 218.2% in the second quarter. Engineers Gate Manager LP now owns 8,143 shares of the company’s stock valued at $953,000 after purchasing an additional 5,584 shares in the last quarter. Insight Wealth Partners LLC purchased a new position in Mirum Pharmaceuticals in the 2nd quarter worth approximately $395,000. Integrated Wealth Concepts LLC purchased a new position in Mirum Pharmaceuticals in the 2nd quarter worth approximately $27,000. Arizona State Retirement System grew its stake in Mirum Pharmaceuticals by 12.6% in the 2nd quarter. Arizona State Retirement System now owns 11,655 shares of the company’s stock worth $1,364,000 after buying an additional 1,306 shares in the last quarter. Finally, Nykredit A S bought a new position in shares of Mirum Pharmaceuticals in the 2nd quarter worth $247,000.

Mirum Pharmaceuticals News Roundup

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Positive Phase 3 data for brelovitug: Mirum said brelovitug met the primary endpoint in the AZURE-1 study for chronic hepatitis delta virus, reporting strong virologic response and alanine aminotransferase normalization rates. The result strengthens the company’s pipeline and potential future growth. Mirum’s Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
• Positive Sentiment: FDA approval for Atebrioz: Mirum reportedly received FDA approval for Atebrioz, adding a regulatory milestone that could support commercial revenue and broaden the company’s product portfolio. Mirum wins FDA approval for Atebrioz
• Positive Sentiment: HC Wainwright raised its long-term earnings outlook and maintained a Buy rating with a $195 price target. Its EPS forecasts increased for fiscal 2027 to $1.42, fiscal 2028 to $5.38, fiscal 2029 to $7.21, and fiscal 2030 to $10.03. Baird also raised its target to $130 and maintained an Outperform rating. Mirum Pharmaceuticals Stock Price Expected to Rise, HC Wainwright Analyst Says
• Neutral Sentiment: Analyst estimates remain mixed in the near term: HC Wainwright raised its Q3 2026 EPS forecast from a loss of $0.31 to positive $0.07 and slightly improved its Q4 2026 estimate, but reduced its Q3 2027 forecast to $0.35 from $0.40. The firm still expects Mirum to report a full-year loss of $1.31.
• Neutral Sentiment: An investor survey comparing Mirum with Sarepta Therapeutics provides additional market commentary but does not represent a material change to Mirum’s fundamentals. Mirum Pharmaceuticals and Sarepta Therapeutics Head-To-Head Survey

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company’s work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum’s primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients.